EV subpopulation identification
Find EV subpopulations with selective biological and therapeutic activities.
About EviCure
Developing extracellular-vesicle therapies for cancer
A pre-clinical biopharmaceutical company combining EV biology, targeted delivery, human disease models and AI.
About us
EviCure is developing extracellular-vesicle (EV) therapies for cancer. Its platform combines EVs with inherent anti-tumor properties and targeted delivery capabilities for different therapeutic payloads.
The development approach centers on identifying active EV subpopulations, using EVs to carry targeted treatments, and advancing scale-up technologies for consistent therapeutic production.
Technology
EviCure's technologies
Three connected capabilities form the core of the platform.
Targeted delivery
Use EVs as vehicles for different types of therapeutic cargo and treatments.
Scale-up
Develop consistent and defined therapeutic EVs with AI-enabled process control.
AI-based scale-up
AI precision at every step
1Discover molecular mechanisms in stem cells and their secreted EVs.
2Identify EV subpopulations with selective tropism and therapeutic effects.
3Scale production using real-time monitoring and AI analysis.
4Translate model results toward human prediction and clinical relevance.
Leadership
Our team
Eric J. Messika
Ph.D., MBA · CEO
Entrepreneur and biotech executive with extensive experience in early-stage life-science companies, immunology and company building.
Aharon Brodie
Ph.D. · CTO
Bioinformatics and data-science specialist with experience in cancer therapeutics, disease analysis, patents and publications.
Chaya Brodie
Ph.D. · Consultant
Research leader in cell and molecular biology with expertise in cancer, stem cells and extracellular vesicles.